HC Wainwright Has Bearish Forecast for Kamada Q2 Earnings

Kamada Ltd. (NASDAQ:KMDA) – HC Wainwright reduced their Q2 2026 EPS estimates for Kamada in a research report issued to clients and investors on Thursday, May 14th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $0.11 per share for the quarter, down from their previous estimate of $0.15. The consensus estimate for Kamada’s current full-year earnings is $0.51 per share. HC Wainwright also issued estimates for Kamada’s Q3 2026 earnings at $0.13 EPS, Q4 2026 earnings at $0.10 EPS and FY2026 earnings at $0.41 EPS.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.05). The business had revenue of $45.24 million during the quarter, compared to analyst estimates of $46.72 million. Kamada had a net margin of 11.21% and a return on equity of 7.73%.

KMDA has been the topic of a number of other research reports. Stifel Nicolaus set a $11.00 target price on shares of Kamada in a research report on Wednesday, March 11th. Weiss Ratings upgraded shares of Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday. Wall Street Zen downgraded shares of Kamada from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Finally, Benchmark reaffirmed a “buy” rating on shares of Kamada in a research note on Thursday, March 12th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Kamada presently has an average rating of “Buy” and a consensus target price of $12.00.

Kamada Stock Performance

Shares of NASDAQ KMDA opened at $7.83 on Tuesday. Kamada has a 1 year low of $6.50 and a 1 year high of $9.35. The firm’s 50 day moving average price is $8.37 and its 200 day moving average price is $7.90. The firm has a market cap of $450.30 million, a P/E ratio of 22.37, a price-to-earnings-growth ratio of 0.60 and a beta of 0.86.

Kamada Dividend Announcement

The company also recently declared an annual dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Monday, March 23rd. This represents a yield of 305.0%. Kamada’s payout ratio is 54.29%.

Institutional Investors Weigh In On Kamada

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KMDA. Jane Street Group LLC purchased a new stake in Kamada during the 1st quarter worth $582,000. Goldman Sachs Group Inc. purchased a new stake in Kamada during the 1st quarter worth $497,000. Essex Investment Management Co. LLC increased its stake in Kamada by 22.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock worth $2,751,000 after buying an additional 72,602 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in Kamada during the 2nd quarter worth $472,000. Finally, Bank of America Corp DE increased its stake in Kamada by 201.0% during the 3rd quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock worth $427,000 after buying an additional 41,111 shares during the period. Hedge funds and other institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.